Építés alatt – nem éles oldal
Belépés
Toborzás még nem indult2. fázis

A Clinical Trial Evaluating Fecal Microbiota Transplantation (FMT) in Adolescents With ADHD

A legfontosabb adatok

Ki végzi
University of Calgary
Hol
Kanada1 helyszín, 1 országbanVálassz országot a helyszínekhez
Azonosító
Állapot
Toborzás még nem indult
Fázis
2. fázis
Résztvevők
64 fő, tervezett
Kezdés
2026. aug. 31.
Várható befejezés
2029. aug. 31.
A vizsgálat típusa
Beavatkozással járó, 4 csoportAz egyik csoport placebót (hatóanyag nélküli szert) kap, összehasonlításként.
A vizsgált kezelések
  • Fecal Microbiota Transplant (FMT)
  • Nitazoxanide 500mg BID
  • Vancomycin 250mg BID
  • Placebo Vancomycin
  • Placebo Nitazoxanide
  • Pico-Salax
  • Placebo Fecal Microbiota Transplantation (FMT)
A regiszteradat frissítve
2026. szeptember 10.

Ki vehet részt

Életkor
13 év – 18 év
Nem
Nők és férfiak
Egészséges önkéntesek
Részt vehetnek

A regiszter feltételei, szó szerint

Mind a 28 feltétel megnézéseKevesebb

Ki vehet részt

  • Between 13-17 years of age with consent of a legal guardian: Participants should be at least 13 years old and not older than 17 years at the day of screening (V1)
  • Have a primary diagnosis of ADHD as confirmed by the Mini-International Neuropsychiatric Interview for Children and Adolescents (MINI-KID)
  • Be on a stable appropriate dose of an appropriate first-line pharmacological treatment for at least 8 weeks prior to the day of screening (V1); First line pharmacotherapy treatment will be defined based on the CADDRA guidelines [63] and include the following; Amphetamine-based psychostimulants:; Mixed amphetamine salts (amphetamine and dextroamphetamine) ii. Lisdexamfetamine dimesylate; Methylphenidate-based psychostimulants:; Methylphenidate hydrochloride, Methylphenidate hydrochloride (extended release, multilayer release capsules) ii. Methylphenidate hydrochloride (extended release, OROS tablets) iii. Methylphenidate hydrochloride (controlled release, multi-layer beat capsules) iv. Methylphenidate hydrochloride (extended-release oral suspension)
  • Have a score of ≥ 18 on the inattention subset (questions 1-9) and/or the hyperactivity/impulsivity subset (questions 10-18) of the SNAP-IV 26-Item Parent Rating Scale on the day of screening (V1) and the baseline visit (V2)
  • Able to communicate and complete study assessments in English
  • Able to comply with all protocol procedures
  • Consenting guardian

Ki nem vehet részt

  • Participant meets Diagnostic and Statistical Manual of Mental Disorders (DSM-5) Criteria for the following conditions according to the MINI-KID:; Diagnosis of a Substance Use Disorder within the last 3 months prior to screening. *(Criteria should include Alcohol and Non-Alcohol substances except Cannabis); Moderate or severe Substance Use Disorder for Cannabis use in the last 3 months; Currently active high suicidality. Eligibility of Participants who meet criteria for moderate suicidality is determined by clinical judgment of Principal Investigator; Active Anorexia Nervosa or Bulimia Nervosa in the last 3 months; Tic Disorders; Psychosis; Obsessive Compulsive Disorder; Bipolar Disorder; Conduct Disorder
  • Intellectual or learning disability based on previous documented diagnosis or clinical judgment of Principal Investigator
  • Use of systemic antibiotics for medical purposes within the last 3 months prior to the day of screening (V1)
  • Use of prebiotics or probiotics for medical purposes for more than 2 weeks within the last 3 months prior to the day of screening (V1); Eligibility and required washout period of participants with use of over-the-counter prebiotics or probiotics will be determined by clinical judgment of Principal Investigator
  • Use of experimental drugs in the last 3 months prior to the day of screening (V1)
  • Documented diagnosis of conditions causing immunosuppression and/or currently receiving immunosuppressive treatments
  • Documented diagnosis of Pediatric Acute-onset Neuropsychiatric Syndrome (PANS) or Pediatric Autoimmune Neuropsychiatric Disorders Associated with Streptococcal Infections (PANDAS)
  • Documented diagnosis of schizophrenia or schizoaffective disorder
  • Documented diagnosis of Autism Spectrum Disorder (ASD) or currently undergoing assessment for suspected ASD
  • Documented clinical diagnosis of inflammatory bowel disease (IBD), Crohn's disease, ulcerative colitis, and/or celiac disease
  • Documented clinical diagnosis of significant bleeding disorders
  • History of oropharyngeal dysphagia or other swallowing disorder, and/or self or study partner reported difficulty with taking oral capsules or pills
  • Reported allergy to Vancomycin or Nitazoxanide
  • Documented history or current diagnosis of an acute or chronic hepatic disease (e.g., cirrhosis, hepatitis, hepatic impairment) OR
  • Abnormal - Liver Function Tests (LFTs): Screening laboratory results indicating clinically significant hepatic dysfunction:
  • Alanine Aminotransferase (ALT) or Aspartate Aminotransferase (AST) ≥3 the Upper Normal Limit (UNL)
  • Total Bilirubin > 1.5 × ULN (except in cases of documented Gilbert's Syndrome) 19. Renal dysfunction: A) Diagnosed Renal Disease: Any documented medical history or current diagnosis of kidney disease, acute kidney injury, or other clinically significant renal impairment. OR B) Abnormal Renal Function Tests: Screening laboratory results indicating significant renal dysfunction. Creatinine > 1.5 × ULN*; Potential participants presenting with mild, non-clinically significant laboratory abnormalities (e.g., AST/ALT between 1.0 and 3.0 × ULN, or isolated borderline creatinine variations confirmation of enrollment into the study will be dependent of the study physician
  • Breastfeeding, pregnant or seeking to get pregnant during the course of this study. Female participants of childbearing age should be using an acceptable method of birth control (implants, injectable, combined oral contraceptives, IUDs, barrier contraceptives, sexual abstinence, or a vasectomized partner) for the duration of their participation in the trial
  • Participant has a score of ≥ 8 on the oppositional defiant subset of the SNAP-IV 26-Item Parent Rating Scale (questions 19-26) on the day of screening (V1)
  • Participants who are currently hospitalized or institutionalized
  • Hepatic dysfunction:

A fő feltételek kérdésként

Magadról válaszolj. Ez nem döntés: hogy részt vehetsz-e, azt csak a vizsgálat csapata mondhatja meg.

  • 13 és 18 év között vagy?

Hol van ez a vizsgálat?

Egy országban van helyszíne. Válassz országot, hogy lásd a helyszíneket.

A vizsgálatról

Mit akar kideríteni a vizsgálat

The primary goals of this phase 2 clinical trial are to determine the feasibility, safety, and tolerability of oral Fecal Microbiota Transplantation (FMT) in adolescents (aged 13-17) with Attention-Deficit/Hyperactivity Disorder (ADHD).

A vizsgálat 4 csoportja

  • Arm 1: Antibiotic, bowel preparation, and FMT receivingA vizsgált kezelés

    Participants receive a 6-day course of antibiotics (nitazoxanide 500 mg BID and vancomycin 250 mg BID), followed by bowel preparation the night prior to fecal microbiota transplantation (FMT), and FMT oral capsules (20 capsules daily for 3 consecutive days).

    Kezelés: Fecal Microbiota Transplant (FMT), Nitazoxanide 500mg BID, Vancomycin 250mg BID és Pico-Salax

  • Arm 2: Antibiotic, bowel preparation, and placebo FMT receivingA vizsgált kezelés

    Participants receive a 6-day course of antibiotic pretreatment (nitazoxanide 500 mg BID and vancomycin 250 mg BID), followed by bowel preparation the night prior to transplantation, and placebo FMT capsules (20 capsules daily for 3 consecutive days).

    Kezelés: Nitazoxanide 500mg BID, Vancomycin 250mg BID, Pico-Salax és Placebo Fecal Microbiota Transplantation (FMT)

  • Arm 3: Placebo antibiotics, bowel preparation, and FMT receivingA vizsgált kezelés

    Participants receive a 6-day course of placebo antibiotic pretreatment (matching nitazoxanide and vancomycin BID), followed by bowel preparation the night prior to transplantation, and oral fecal microbiota transplantation (FMT) capsules (20 capsules daily for 3 consecutive days).

    Kezelés: Fecal Microbiota Transplant (FMT), Placebo Vancomycin, Placebo Nitazoxanide és Pico-Salax

  • Arm 4: Placebo antibiotic, bowel preparation, and placebo FMT receivingPlacebo, összehasonlításként

    Participants receive a 6-day course of placebo antibiotic pretreatment (matching nitazoxanide and vancomycin BID), followed by bowel preparation the night prior to transplantation, and placebo FMT capsules (20 capsules daily for 3 consecutive days).

    Kezelés: Placebo Vancomycin, Placebo Nitazoxanide, Pico-Salax és Placebo Fecal Microbiota Transplantation (FMT)

Kérdések a vizsgálat csapatának

  1. Milyen gyakran kell bejárnom, és egy-egy alkalom mennyi ideig tart?
  2. Megtérítik az utazási költséget?
  3. Megtarthatom a saját orvosomat?
  4. Mi történik, ha ki akarok lépni?

Contact the study team: see the registry record → Contacts and Locations

Oldal nyomtatása az orvosomnak

Adatok és források

Regiszteradat
Szerepel a ClinicalTrials.gov-on.
Hivatalos cím
Feasibility, Safety and Tolerability of Fecal Microbiota Transplantation in an Adolescent Population With Attention Deficit Hyperactivity Disorder (ADHD)
Kérdések a feltételekről
Forrás: NCT07756255: ki vehet részt
A regiszteradat frissítve
2026. szeptember 10.